Wyeth Taps Pharmacopeia Technology For Potential Small Molecule RA Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
The two firms will each develop and commercialize products resulting from research based on Pharmacopeia’s JAK3 inhibitor program.
You may also be interested in...
Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.
Pharmacopeia Targets 2009 For SARM Phase II After Gaining Program From Bristol
Company licenses the Phase I selective androgen receptor modulator for muscle wasting from Bristol in exchange for research support.
Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says
Company says it is in active licensing discussions with “probably half a dozen” firms.